Bio-Techne (TECH) 10-Q 6 Nov 19 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2019	Nov. 01, 2019
Document Information [Line Items]
Entity Central Index Key	0000842023
Entity Registrant Name	BIO-TECHNE Corp
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	0-17272
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1427402
Entity Address, Address Line One	614 McKinley Place N.E.
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55413
City Area Code	612
Local Phone Number	379-8854
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	TECH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,112,184

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Net sales	$ 183,243	$ 162,970
Cost of sales	64,829	55,367
Gross margin	118,414	107,603
Operating expenses:
Selling, general and administrative	69,010	67,051
Research and development	16,077	14,789
Total operating expenses	85,087	81,840
Operating income	33,327	25,763
Other (expense) income	(15,521)	(8,177)
Earnings before income taxes	17,806	17,586
Income taxes	3,408	183
Net earnings	14,398	17,403
Other comprehensive (loss) income:
Foreign currency translation adjustments	(7,602)	(1,136)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax of $154 in FY20	(504)	0
Other comprehensive (loss) income	(8,106)	(1,136)
Comprehensive income	$ 6,292	$ 16,267
Earnings per share:
Basic (in dollars per share)	$ 0.38	$ 0.46
Diluted (in dollars per share)	$ 0.37	$ 0.45
Weighted average common shares outstanding:
Basic (in shares)	38,032	37,697
Diluted (in shares)	39,253	38,813

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Sep. 30, 2019USD ($)
Unrealized gains (losses) on derivative instruments - cash flow hedges, tax	$ 154

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 99,891	$ 100,886
Short-term available-for-sale investments	58,520	65,147
Accounts receivable, less allowance for doubtful accounts of $1,007 and $980, respectively	122,724	137,466
Inventories	90,855	91,050
Other current assets	19,955	18,058
Total current assets	391,945	412,607
Property and equipment, net	156,783	154,039
Right of use asset	76,962	0
Goodwill	730,412	732,667
Intangible assets, net	563,338	579,429
Other assets	5,588	5,668
Total assets	1,925,028	1,884,410
Current liabilities:
Trade accounts payable	14,106	16,210
Salaries, wages and related accruals	17,543	28,638
Accrued expenses	11,048	26,389
Contract liabilities	9,108	9,084
Income taxes payable	6,533	5,764
Operating lease liabilities - current	9,260	0
Contingent consideration payable	8,170	3,400
Current portion of long-term debt obligations	12,500	12,500
Total current liabilities	88,268	101,985
Deferred income taxes	88,530	89,754
Long-term debt obligations	473,556	492,660
Long-term contingent consideration payable	5,130	9,200
Operating lease liabilities	72,870	0
Other long-term liabilities	22,450	25,222
Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 38,084,292 and 37,934,040, respectively	381	379
Additional paid-in capital	334,112	316,797
Retained earnings	931,358	931,934
Accumulated other comprehensive loss	(91,627)	(83,521)
Total shareholders' equity	1,174,224	1,165,589
Total liabilities and shareholders’ equity	$ 1,925,028	$ 1,884,410

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Accounts receivable, allowance for doubtful accounts	$ 1,007	$ 980
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	38,084,292	37,934,040
Common stock, shares outstanding (in shares)	38,084,292	37,934,040

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ 14,398	$ 17,403
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	20,085	19,052
Costs recognized on sale of acquired inventory	0	935
Deferred income taxes	(607)	(3,768)
Stock-based compensation expense	8,366	11,565
Fair value adjustment to contingent consideration payable	700	(200)
Fair value adjustment on available for sale investments	10,401	2,202
Other operating activity	164	2,217
Change in operating assets and operating liabilities, net of acquisition:
Trade accounts and other receivables, net	(1,405)	8,307
Inventories	(720)	(6,678)
Other current assets	(2,549)	(1,354)
Trade accounts payable, accrued expenses, contract liabilities, and other	1,456	3,107
Salaries, wages and related accruals	(10,983)	(8,476)
Income taxes payable	1,233	(4,864)
Net cash provided by operating activities	40,539	39,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturities of available-for-sale investments	11,311	0
Purchases of available-for-sale investments	(15,871)	(11,694)
Additions to property and equipment	(10,525)	(4,190)
Acquisitions, net of cash acquired	0	(272,229)
Net cash used in investing activities	(15,085)	(288,113)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends	(12,169)	(12,066)
Proceeds from stock option exercises	8,952	16,453
Proceeds from long-term debt	0	580,000
Repayments of long-term debt	(19,125)	(357,125)
Debt issuance costs	0	(3,004)
Other financing activity	(1,927)	(1,727)
Net cash provided by (used in) financing activities	(24,269)	222,531
Effect of exchange rate changes on cash and cash equivalents	(2,180)	(1,182)
Net decrease in cash and cash equivalents	(995)	(27,316)
Cash and cash equivalents at beginning of period	100,886	121,990
Cash and cash equivalents at end of period	99,891	94,674
Supplemental disclosure of cash flow information:
Cash paid for income taxes	2,452	8,447
Cash paid for interest	$ 5,092	$ 3,229

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10 10 X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2019, 10 2019. 10 2019. During the first 2020, two 10 2019. Recently Adopted Accounting Pronouncements In February 2016, 2016 02, 842 842 No. 2018 10 2019 01. 2018 11, not 2018 11 842 July 1, 2019 $4.0 840 842. 842, 842, not 12 7 Pronouncements Issued But Not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2. Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no not not not not not third third The Company elected the exemption to not one not September 30, 2019. Contracts with customers that contain instruments may Payment terms for shipments to end-users are generally net 30 may 30 90 Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one one September 30, 2019 not Con tract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of September 30, 2019 June 30, 2019 June 30, 2019 September 30, 2019 3.8 million. Contract liabilities in excess of one Any claims for credit or return of goods must be made within 10 not Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: Quarter Ended September 30, 2019 2018 Consumables $ 151,445 $ 135,653 Instruments 16,993 15,346 Services 10,623 8,301 Total product and services revenue, net $ 179,061 $ 159,299 Royalty revenues 4,182 3,671 Total revenues, net $ 183,243 $ 162,970 Revenue by geography is as follows: Quarter Ended September 30, 2019 2018 United States $ 102,352 $ 90,455 EMEA, excluding United Kingdom 38,804 35,233 United Kingdom 7,589 7,128 APAC, excluding Greater China 14,005 11,629 Greater China 16,080 13,422 Rest of World 4,413 5,103 Total revenues, net $ 183,243 $ 162,970

Note 3 - Selected Balance Sheet

Note 3 - Selected Balance Sheet Data	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3. Inventories: Inventories consist of (in thousands): September 30, June 30, 2019 201 9 Raw materials $ 41,178 $ 40,913 Finished goods (1) 53,044 53,376 Inventories, net $ 94,222 $ 94,289 ( 1 September 30, 2019 June 30, 2019, 12 Property and Equipment: Property and equipment consist of (in thousands): September 30, June 30, 2019 201 9 Land $ 7,561 $ 7,065 Buildings and improvements 175,493 175,019 Machinery and equipment 130,682 124,233 Property and equipment, cost 313,736 306,317 Accumulated depreciation and amortization (156,953 ) (152,278 ) Property and equipment, net $ 156,783 $ 154,039 Intangible Assets: Intangible assets consist of (in thousands): September 30, June 30, 2019 201 9 Developed technology $ 434,901 $ 435,679 Trade names 146,950 147,296 Customer relationships 212,913 214,320 Patents 2,242 2,133 Intangible assets 797,006 799,428 Accumulated amortization (233,668 ) (219,999 ) Intangible assets, net $ 563,338 $ 579,429 Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2019 Beginning balance $ 579,429 Acquisitions - Other additions 72 Amortization expense (14,949 ) Currency translation (1,214 ) Ending balance $ 563,338 The estimated future amortization expense for intangible assets as of September 30, 2019 2020 remainder $ 44,807 2021 59,403 2022 57,804 2023 55,938 2024 53,409 Thereafter 291,977 Total $ 563,338 Goodwill: Changes to the carrying amount of goodwill for the quarter ended September 30, 2019 Protein Sciences Diagnostics and Genomics Total Beginning balance $ 377,407 355,260 $ 732,667 Acquisitions (Note 4) - - - Currency translation (2,150 ) (105 ) (2,255 ) Ending balance $ 375,257 $ 355,155 $ 730,412 We evaluate the carrying value of goodwill in the fourth fourth 2019. No No September 30, 2019. no 350 July 1, 2002.

Note 4 - Acquisitions

Note 4 - Acquisitions	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4. We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and the results of operations of each acquired business are included in our consolidated statements of comprehensive income from their respective dates of acquisition. Acquisition costs are recorded in selling, general and administrative expenses as incurred. B-MoGen Biotechnologies On June 4, 2019, 10K/A. not fourth 2019. Certain estimated fair values are not second 2020 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 504 Equipment and other long-term assets 269 Intangible assets: Developed technology 14,000 Customer relationships 400 Goodwill 16,457 Total assets acquired 31,630 Liabilities 211 Deferred income taxes, net 3,377 Net assets acquired $ 28,042 Cash paid, net of cash acquired $ 17,448 Fair value of contingent consideration 5,500 Fair value of historical investment in B-MoGen 5,094 Net assets acquired $ 28,042 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 5. The Company’s financial instruments include cash and cash equivalents, available for sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value as of Fair Value Measurements Using Inputs Considered as September 30, 2019 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 27,819 $ 27,819 $ - $ - Certificates of deposit (2) 30,701 30,701 - - Total assets $ 58,520 $ 58,520 $ - $ - Liabilities Contingent consideration $ 13,300 $ - $ - $ 13,300 Derivative instruments - cash flow hedges 13,116 - 13,116 - Total liabilities $ 26,416 $ - $ 13,116 $ 13,300 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2019 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 38,219 $ 38,219 $ - $ - Certificates of deposit (2) 26,928 26,928 - - Total assets $ 65,147 $ 65,147 $ - $ - Liabilities Contingent consideration $ 12,600 $ - $ - $ 12,600 Derivative instruments - cash flow hedges 12,458 - 12,458 - Total liabilities $ 25,058 $ - $ 12,458 $ 12,600 ( 1 Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) at September 30, 2019 June 30, 2019 ( 2 Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one Fair value measurements of available for sale securities Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 Fair value measurements of derivative instruments In October 2018, 6 no September 30, 2019. 2 Fair value measurements of contingent consideration In connection with the Exosome Diagnostics, Inc. (Exosome), QT Holdings Corporation (Quad), and B-MoGen acquisitions the Company is required to make contingent consideration payments of up to $325.0 million, $51.0 million and $38.0 million, respectively. The contingent consideration payments are subject to Exosome achieving certain EBITA thresholds, Quad meeting certain product development milestones and revenue thresholds, and B-Mogen meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $14.6 million ($3.8 million for Exosome, $5.3 million for Quad, and $5.5 million for B-MoGen). The preliminary fair value of the development milestone payments was estimated by discounting to present value the probability-weighted contingent payments expected to be made. Assumptions used in these calculations were probability of success, duration of the earn-out, and discount rate. The preliminary fair value for the EBITA and revenue milestone payments was determined using a Monte Carlo simulation based model discounted to present value. Assumptions used in these calculation included units sold, expected revenue, expected expenses, discount rate and various probability factors. The ultimate settlement of contingent consideration could deviate from current estimates based on the actual results of these financial measures. This liability is considered to be a Level 3 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 September 30, 2019 ( Quarter Ended September 30, 2019 Fair value at the beginning of period $ 12,600 Purchase price contingent consideration (Note 4) - Change in fair value of contingent consideration 700 Payments - Fair value at the end of period $ 13,300 The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may may Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility approximates fair value because our interest rate is variable and reflects current market rates.

Note 6 - Debt and Other Financi

Note 6 - Debt and Other Financing Arrangements	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6. On August 1, 2018, may The Credit Agreement matures on August 1, 2023 September 30, 2019,

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 7. As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016 02 842, Leases July 1, 2019. The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne’s incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the three September 30, 2019, The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands): Balance Sheet Classification As of: September 30, 2019 Operating leases: Operating lease right of use assets Right of Use Asset $ 76,962 Current operating lease liabilities Operating lease liabilities current $ 9,260 Noncurrent operating lease liabilities Operating lease liabilities 72,870 Total operating lease liabilities $ 82,130 Weighted average remaining lease term (in years): 9.33 Weighted average discount rate: 4.40 % The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the three Three months ended September 30, 2019 Cash amounts paid on operating lease liabilities $ 3,144 Right of use assets obtained in exchange for lease liabilities 25 The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands): Operating Leases Remainder of 2020 $ 6,856 2021 9,017 2022 8,893 2023 8,616 2024 8,170 Thereafter 40,578 Total $ 82,130 Certain leases include one five not Disclosures related to periods prior to adoption of new lease standard: At June 30, 2019, one Operating Leases 2020 $ 13,707 2021 13,469 2022 13,154 2023 12,716 2024 11,392 Thereafter 51,895 Total $ 116,333 Total rent expense was approximately $12.9 million, $10.8 million, and $9.8 million for the years ended June 30, 2019, 2018, 2017,

Note 8 - Supplemental Equity an

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss): Supplemental Equity The Company has declared cash dividends per share of $0.32 in both the three September 30, 2019 2018. Consolidated Changes in Equity (amounts in thousands) Accumulated Additional Other Common Stock Paid-in Retained Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2019 37,934 $ 379 $ 316,797 $ 931,934 $ (83,521 ) $ 1,165,589 Cumulative effect adjustments due to adoption of new accounting standards and other (879 ) (879 ) Net earnings 14,398 14,398 Other comprehensive loss (8,106 ) (8,106 ) Common stock issued for exercise of options 94 1 7,854 7,855 Common stock issued for restricted stock awards 50 0 (0 ) (1,926 ) (1,926 ) Cash dividends (12,169 ) (12,169 ) Stock-based compensation expense 8,267 8,267 Common stock issued to employee stock purchase plan 6 0 1,096 1,096 Employee stock purchase plan expense 99 99 Balances at September 30, 2019 38,084 $ 381 $ 334,112 $ 931,358 $ (91,627 ) $ 1,174,224 Accumulated Additional Other Common Stock Paid-in Retained Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2018 37,608 $ 376 $ 246,568 $ 876,931 $ (44,814 ) $ 1,079,061 Cumulative effect adjustments due to adoption of new accounting standards and other 25,276 (24,682 ) 594 Net earnings 17,403 17,403 Other comprehensive loss (1,136 ) (1,136 ) Common stock issued for exercise of options 166 2 15,609 15,611 Common stock issued for restricted stock awards 24 0 (2,405 ) (2,405 ) Cash dividends (12,066 ) (12,066 ) Stock-based compensation expense 11,327 11,327 Common stock issued to employee stock purchase plan 5 0 842 842 Employee stock purchase plan expense 238 238 Balances at September 30, 2018 37,803 $ 378 $ 274,584 $ 905,139 $ (70,632 ) $ 1,109,469 Accumulated Other Comprehensive Income The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges entered into in the second 2019. three September 30, 2019 2018. The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Unrealized Gains (Losses) on Derivative Instruments Foreign Currency Translation Adjustments Total Balance as of June 30, 2019 $ (9,537 ) $ (73,983 ) $ (83,521 ) Other comprehensive income (loss), net of tax before reclassifications (504 ) (7,602 ) (8,106 ) Balance as of September 30, 2019 (1) $ (10,041 ) $ (81,585 ) $ (91,627 ) Unrealized Gains (Losses) on Derivative Instruments Foreign Currency Translation Adjustments Total Balance as of June 30, 2018 (2) $ - $ (69,496 ) $ (69,496 ) Other comprehensive income (loss), net of tax before reclassifications - (1,136 ) (1,136 ) Balance as of September 30, 2018 $ - $ (70,632 ) $ (70,632 ) ( 1 October 31, 2019. 12 September 30, 2019. ( 2 10 June 30, 2018 2019 2016 01 2018 02. June 30, 2018

Note 9 - Earnings Per Share

Note 9 - Earnings Per Share	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Quarter Ended September 30, 2019 2018 Earnings per share – basic: Net Income $ 14,398 $ 17,403 Income allocated to participating securities (11 ) (16 ) Income available to common shareholders $ 14,387 $ 17,387 Weighted-average shares outstanding 38,032 37,697 Earnings per share-basic $ 0.38 $ 0.46 Earnings per share – diluted: Net Income $ 14,398 $ 17,403 Income allocated to participating securities (11 ) (16 ) Income available to common shareholders $ 14,387 $ 17,387 Weighted average common shares outstanding-basic 38,032 37,697 Dilutive effect of stock options and restricted stock units 1,221 1,116 Weighted average common shares outstanding-diluted 39,253 38,813 Earnings per share-diluted $ 0.37 $ 0.45 The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 1.2 million and 1.3 million for the first September 30, 2019 2018,

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 10. During the quarter ended September 30, 2019 2018, September 30, 2019 2018, September 30, 2019 2018, Stock options for 93,596 and 166,577 shares of common stock with total intrinsic values of $11.6 million and $14.9 million were exercised during the quarter ended September 30, 2019 2018, Stock-based compensation expense of $8.4 million and $11.6 million was included in selling, general and administrative expenses for the quarter ended September 30, 2019 2018, September 30, 2019,

Note 11 - Other Income _ (Expen

Note 11 - Other Income / (Expense)	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	Note 11. The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows: Quarter Ended September 30, 2019 2018 Interest expense $ (5,222 ) $ (5,239 ) Interest income 111 102 Other non-operating income (expense), net (10,410 ) (3,040 ) Total other income (expense) $ (15,521 ) $ (8,177 )

Note 12 - Income Taxes

Note 12 - Income Taxes	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 12. The Company’s effective income tax rate for the first 2020 2019 first 2020 first 2019 The Company recognized total net benefits related to discrete tax items of $1.3 million during the three September 30, 2019 three September 30, 2018. three September 30, 2019 2018, three September 30, 2018. The Company continues to monitor changes in interpretations, assumptions guidance, and additional regulations regarding the Tax Cuts and Jobs Act (the “Tax Act”), which was enacted on December 22, 2017.

Note 13 - Segment Information

Note 13 - Segment Information	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 13. The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): Quarter Ended September 30, 2019 2018 Net sales: Protein Sciences $ 140,995 $ 126,391 Diagnostics and Genomics 42,552 36,747 Intersegment (304 ) (168 ) Consolidated net sales $ 183,243 $ 162,970 Operating income: Protein Sciences $ 59,538 $ 54,614 Diagnostics and Genomics 900 2,536 Segment operating income 60,438 57,150 Costs recognized on sale of acquired inventory - (935 ) Amortization of acquisition related intangible assets (14,901 ) (14,276 ) Acquisition related expenses (1,310 ) (2,631 ) Stock-based compensation, inclusive of employer taxes (8,800 ) (11,565 ) Corporate general, selling, and administrative expenses (2,100 ) (1,980 ) Consolidated operating income $ 33,327 $ 25,763

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 1 4 . Subsequent Events : None.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In February 2016, 2016 02, 842 842 No. 2018 10 2019 01. 2018 11, not 2018 11 842 July 1, 2019 $4.0 840 842. 842, 842, not 12 7 Pronouncements Issued But Not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Quarter Ended September 30, 2019 2018 Consumables $ 151,445 $ 135,653 Instruments 16,993 15,346 Services 10,623 8,301 Total product and services revenue, net $ 179,061 $ 159,299 Royalty revenues 4,182 3,671 Total revenues, net $ 183,243 $ 162,970 Quarter Ended September 30, 2019 2018 United States $ 102,352 $ 90,455 EMEA, excluding United Kingdom 38,804 35,233 United Kingdom 7,589 7,128 APAC, excluding Greater China 14,005 11,629 Greater China 16,080 13,422 Rest of World 4,413 5,103 Total revenues, net $ 183,243 $ 162,970

Note 3 - Selected Balance She_2

Note 3 - Selected Balance Sheet Data (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, June 30, 2019 201 9 Raw materials $ 41,178 $ 40,913 Finished goods (1) 53,044 53,376 Inventories, net $ 94,222 $ 94,289
Property, Plant and Equipment [Table Text Block]	September 30, June 30, 2019 201 9 Land $ 7,561 $ 7,065 Buildings and improvements 175,493 175,019 Machinery and equipment 130,682 124,233 Property and equipment, cost 313,736 306,317 Accumulated depreciation and amortization (156,953 ) (152,278 ) Property and equipment, net $ 156,783 $ 154,039
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, June 30, 2019 201 9 Developed technology $ 434,901 $ 435,679 Trade names 146,950 147,296 Customer relationships 212,913 214,320 Patents 2,242 2,133 Intangible assets 797,006 799,428 Accumulated amortization (233,668 ) (219,999 ) Intangible assets, net $ 563,338 $ 579,429
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Beginning balance $ 579,429 Acquisitions - Other additions 72 Amortization expense (14,949 ) Currency translation (1,214 ) Ending balance $ 563,338
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2020 remainder $ 44,807 2021 59,403 2022 57,804 2023 55,938 2024 53,409 Thereafter 291,977 Total $ 563,338
Schedule of Goodwill [Table Text Block]	Protein Sciences Diagnostics and Genomics Total Beginning balance $ 377,407 355,260 $ 732,667 Acquisitions (Note 4) - - - Currency translation (2,150 ) (105 ) (2,255 ) Ending balance $ 375,257 $ 355,155 $ 730,412

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Allocation at Acquisition Date Current assets, net of cash $ 504 Equipment and other long-term assets 269 Intangible assets: Developed technology 14,000 Customer relationships 400 Goodwill 16,457 Total assets acquired 31,630 Liabilities 211 Deferred income taxes, net 3,377 Net assets acquired $ 28,042 Cash paid, net of cash acquired $ 17,448 Fair value of contingent consideration 5,500 Fair value of historical investment in B-MoGen 5,094 Net assets acquired $ 28,042

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value as of Fair Value Measurements Using Inputs Considered as September 30, 2019 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 27,819 $ 27,819 $ - $ - Certificates of deposit (2) 30,701 30,701 - - Total assets $ 58,520 $ 58,520 $ - $ - Liabilities Contingent consideration $ 13,300 $ - $ - $ 13,300 Derivative instruments - cash flow hedges 13,116 - 13,116 - Total liabilities $ 26,416 $ - $ 13,116 $ 13,300 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2019 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 38,219 $ 38,219 $ - $ - Certificates of deposit (2) 26,928 26,928 - - Total assets $ 65,147 $ 65,147 $ - $ - Liabilities Contingent consideration $ 12,600 $ - $ - $ 12,600 Derivative instruments - cash flow hedges 12,458 - 12,458 - Total liabilities $ 25,058 $ - $ 12,458 $ 12,600
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Quarter Ended September 30, 2019 Fair value at the beginning of period $ 12,600 Purchase price contingent consideration (Note 4) - Change in fair value of contingent consideration 700 Payments - Fair value at the end of period $ 13,300

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Lessee, Operating Lease, Asset and Liabilities [Table Text Block]	Balance Sheet Classification As of: September 30, 2019 Operating leases: Operating lease right of use assets Right of Use Asset $ 76,962 Current operating lease liabilities Operating lease liabilities current $ 9,260 Noncurrent operating lease liabilities Operating lease liabilities 72,870 Total operating lease liabilities $ 82,130 Weighted average remaining lease term (in years): 9.33 Weighted average discount rate: 4.40 %
Lessee, Operating Lease, Cash Flow Information [Table Text Block]	Three months ended September 30, 2019 Cash amounts paid on operating lease liabilities $ 3,144 Right of use assets obtained in exchange for lease liabilities 25
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Leases Remainder of 2020 $ 6,856 2021 9,017 2022 8,893 2023 8,616 2024 8,170 Thereafter 40,578 Total $ 82,130
Lessee, Operating Lease, Disclosure [Table Text Block]	Operating Leases 2020 $ 13,707 2021 13,469 2022 13,154 2023 12,716 2024 11,392 Thereafter 51,895 Total $ 116,333

Note 8 - Supplemental Equity _2

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Consolidated Stockholders' Equity Statement [Table Text Block]	Accumulated Additional Other Common Stock Paid-in Retained Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2019 37,934 $ 379 $ 316,797 $ 931,934 $ (83,521 ) $ 1,165,589 Cumulative effect adjustments due to adoption of new accounting standards and other (879 ) (879 ) Net earnings 14,398 14,398 Other comprehensive loss (8,106 ) (8,106 ) Common stock issued for exercise of options 94 1 7,854 7,855 Common stock issued for restricted stock awards 50 0 (0 ) (1,926 ) (1,926 ) Cash dividends (12,169 ) (12,169 ) Stock-based compensation expense 8,267 8,267 Common stock issued to employee stock purchase plan 6 0 1,096 1,096 Employee stock purchase plan expense 99 99 Balances at September 30, 2019 38,084 $ 381 $ 334,112 $ 931,358 $ (91,627 ) $ 1,174,224 Accumulated Additional Other Common Stock Paid-in Retained Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2018 37,608 $ 376 $ 246,568 $ 876,931 $ (44,814 ) $ 1,079,061 Cumulative effect adjustments due to adoption of new accounting standards and other 25,276 (24,682 ) 594 Net earnings 17,403 17,403 Other comprehensive loss (1,136 ) (1,136 ) Common stock issued for exercise of options 166 2 15,609 15,611 Common stock issued for restricted stock awards 24 0 (2,405 ) (2,405 ) Cash dividends (12,066 ) (12,066 ) Stock-based compensation expense 11,327 11,327 Common stock issued to employee stock purchase plan 5 0 842 842 Employee stock purchase plan expense 238 238 Balances at September 30, 2018 37,803 $ 378 $ 274,584 $ 905,139 $ (70,632 ) $ 1,109,469
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Derivative Instruments Foreign Currency Translation Adjustments Total Balance as of June 30, 2019 $ (9,537 ) $ (73,983 ) $ (83,521 ) Other comprehensive income (loss), net of tax before reclassifications (504 ) (7,602 ) (8,106 ) Balance as of September 30, 2019 (1) $ (10,041 ) $ (81,585 ) $ (91,627 ) Unrealized Gains (Losses) on Derivative Instruments Foreign Currency Translation Adjustments Total Balance as of June 30, 2018 (2) $ - $ (69,496 ) $ (69,496 ) Other comprehensive income (loss), net of tax before reclassifications - (1,136 ) (1,136 ) Balance as of September 30, 2018 $ - $ (70,632 ) $ (70,632 )

Note 9 - Earnings Per Share (Ta

Note 9 - Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarter Ended September 30, 2019 2018 Earnings per share – basic: Net Income $ 14,398 $ 17,403 Income allocated to participating securities (11 ) (16 ) Income available to common shareholders $ 14,387 $ 17,387 Weighted-average shares outstanding 38,032 37,697 Earnings per share-basic $ 0.38 $ 0.46 Earnings per share – diluted: Net Income $ 14,398 $ 17,403 Income allocated to participating securities (11 ) (16 ) Income available to common shareholders $ 14,387 $ 17,387 Weighted average common shares outstanding-basic 38,032 37,697 Dilutive effect of stock options and restricted stock units 1,221 1,116 Weighted average common shares outstanding-diluted 39,253 38,813 Earnings per share-diluted $ 0.37 $ 0.45

Note 11 - Other Income _ (Exp_2

Note 11 - Other Income / (Expense) (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Quarter Ended September 30, 2019 2018 Interest expense $ (5,222 ) $ (5,239 ) Interest income 111 102 Other non-operating income (expense), net (10,410 ) (3,040 ) Total other income (expense) $ (15,521 ) $ (8,177 )

Note 13 - Segment Information (

Note 13 - Segment Information (Tables)	3 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Quarter Ended September 30, 2019 2018 Net sales: Protein Sciences $ 140,995 $ 126,391 Diagnostics and Genomics 42,552 36,747 Intersegment (304 ) (168 ) Consolidated net sales $ 183,243 $ 162,970 Operating income: Protein Sciences $ 59,538 $ 54,614 Diagnostics and Genomics 900 2,536 Segment operating income 60,438 57,150 Costs recognized on sale of acquired inventory - (935 ) Amortization of acquisition related intangible assets (14,901 ) (14,276 ) Acquisition related expenses (1,310 ) (2,631 ) Stock-based compensation, inclusive of employer taxes (8,800 ) (11,565 ) Corporate general, selling, and administrative expenses (2,100 ) (1,980 ) Consolidated operating income $ 33,327 $ 25,763

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Jul. 01, 2019	Sep. 30, 2019	Jun. 30, 2019
Operating Lease, Liability, Total		$ 82,130
Operating Lease, Right-of-Use Asset		76,962	$ 0
Retained Earnings (Accumulated Deficit), Ending Balance		931,358	931,934
Deferred Tax Liabilities, Net, Noncurrent		$ 88,530	$ 89,754
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total	$ 80,600
Operating Lease, Right-of-Use Asset	79,500
Retained Earnings (Accumulated Deficit), Ending Balance	800
Deferred Tax Liabilities, Net, Noncurrent	300
Reclassification from Deferred Rent Recorded Within Accrued Expenses to Operating Lease Liabilities [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 4,000

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019
Contract with Customer, Liability, Total	$ 10.5	$ 10.4
Contract with Customer, Liability, Revenue Recognized	$ 3.8

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Revenues, net	$ 183,243	$ 162,970
UNITED STATES
Revenues, net	102,352	90,455
EMEA, excluding U.K. [Member]
Revenues, net	38,804	35,233
UNITED KINGDOM
Revenues, net	7,589	7,128
APAC, excluding Greater China [Member]
Revenues, net	14,005	11,629
CHINA
Revenues, net	16,080	13,422
Rest of World [Member]
Revenues, net	4,413	5,103
Consumables [Member]
Revenues, net	151,445	135,653
Instruments [Member]
Revenues, net	16,993	15,346
Service [Member]
Revenues, net	10,623	8,301
Product and Services [Member]
Revenues, net	179,061	159,299
Royalty [Member]
Revenues, net	$ 4,182	$ 3,671

Note 3 - Selected Balance She_3

Note 3 - Selected Balance Sheet Data (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Other Noncurrent Assets [Member]
Inventory, Finished Goods, Net of Reserves, Non-current	$ 3,367	$ 3,239

Note 3 - Selected Balance She_4

Note 3 - Selected Balance Sheet Data - Inventories (Details) - USD ($) $ in Thousands		Sep. 30, 2019	Jun. 30, 2019
Raw materials		$ 41,178	$ 40,913
Finished goods	[1]	53,044	53,376
Inventories, net		$ 94,222	$ 94,289
[1]	Finished goods inventory of $3,367 and $3,239 is included within other long-term assets in the respective September 30, 2019 and June 30, 2019, consolidated balance sheet. The inventory is included in long-term assets as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Note 3 - Selected Balance She_5

Note 3 - Selected Balance Sheet Data - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Property and equipment, cost	$ 313,736	$ 306,317
Accumulated depreciation and amortization	(156,953)	(152,278)
Property and equipment, net	156,783	154,039
Land [Member]
Property and equipment, cost	7,561	7,065
Building and Building Improvements [Member]
Property and equipment, cost	175,493	175,019
Machinery and Equipment [Member]
Property and equipment, cost	$ 130,682	$ 124,233

Note 3 - Selected Balance She_6

Note 3 - Selected Balance Sheet Data - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Intangible assets	$ 797,006	$ 799,428
Accumulated amortization	(233,668)	(219,999)
Intangible assets, net	563,338	579,429
Developed Technology Rights [Member]
Intangible assets	434,901	435,679
Trade Names [Member]
Intangible assets	146,950	147,296
Customer Relationships [Member]
Intangible assets	212,913	214,320
Patents [Member]
Intangible assets	$ 2,242	$ 2,133

Note 3 - Selected Balance She_7

Note 3 - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2019USD ($)
Beginning balance	$ 579,429
Acquisitions	0
Other additions	72
Amortization expense	(14,949)
Currency translation	(1,214)
Ending balance	$ 563,338

Note 3 - Selected Balance She_8

Note 3 - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Sep. 30, 2019USD ($)
2020 remainder	$ 44,807
2021	59,403
2022	57,804
2023	55,938
2024	53,409
Thereafter	291,977
Total	$ 563,338

Note 3 - Selected Balance She_9

Note 3 - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2019USD ($)
Balance	$ 732,667
Acquisitions (Note 4)	0
Currency translation	(2,255)
Balance	730,412
Protein Sciences [Member]
Balance	377,407
Acquisitions (Note 4)	0
Currency translation	(2,150)
Balance	375,257
Diagnostics and Genomics [Member]
Balance	355,260
Acquisitions (Note 4)	0
Currency translation	(105)
Balance	$ 355,155

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands	Jun. 04, 2019	Sep. 30, 2019	Sep. 30, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 0	$ 272,229
B-MoGen [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 17,448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	38,000	$ 38,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value	1,400
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain	$ 3,700
B-MoGen [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	14 years

Note 4 - Acquisitions - Prelimi

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019
Goodwill		$ 730,412		$ 732,667
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 0	$ 272,229
B-MoGen [Member]
Current assets, net of cash	$ 504
Equipment and other long-term assets	269
Goodwill	16,457
Total assets acquired	31,630
Liabilities	211
Deferred income taxes, net	3,377
Net assets acquired	28,042
Payments to Acquire Businesses, Net of Cash Acquired, Total	17,448
Fair value of contingent consideration	5,500
Fair value of historical investment in B-MoGen	5,094
Net assets acquired	28,042
B-MoGen [Member] | Developed Technology Rights [Member]
Intangible assets	14,000
B-MoGen [Member] | Customer Relationships [Member]
Intangible assets	$ 400

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Jun. 04, 2019	Oct. 31, 2018	Aug. 01, 2018	Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized			$ 14,600
Exosome Diagnostics, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 325,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					$ 3,800
QT Holdings Corporation [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized						$ 5,300
B-MoGen [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	38,000		38,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized			$ 5,500
Embedded Derivative Financial Instruments [Member]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount				$ 380,000
CCXI [Member]
Investments, Total	$ 18,800	$ 18,800

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2019	Jun. 30, 2019
Total assets		$ 58,520	$ 65,147
Contingent consideration		13,300	12,600
Derivative instruments - cash flow hedges		13,116	12,458
Total liabilities		26,416	25,058
Fair Value, Inputs, Level 1 [Member]
Total assets		58,520	65,147
Contingent consideration		0	0
Derivative instruments - cash flow hedges		0	0
Total liabilities		0	0
Fair Value, Inputs, Level 2 [Member]
Total assets		0	0
Contingent consideration		0	0
Derivative instruments - cash flow hedges		13,116	12,458
Total liabilities		13,116	12,458
Fair Value, Inputs, Level 3 [Member]
Total assets		0	0
Contingent consideration		13,300	12,600
Derivative instruments - cash flow hedges		0	0
Total liabilities		13,300	12,600
Equity Securities [Member]
Investments, Fair Value Disclosure	[1]	27,819	38,219
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	27,819	38,219
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]	0	0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]	0	0
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	[2]	30,701	26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[2]	30,701	26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[2]	0	0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[2]	$ 0	$ 0
[1]	Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) at September 30, 2019 and June 30, 2019 was $18.8 million
[2]	Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] $ in Thousands	3 Months Ended
	Sep. 30, 2019USD ($)
Fair value at the beginning of period	$ 12,600
Purchase price contingent consideration (Note 4)	0
Change in fair value of contingent consideration	700
Payments	0
Fair value at the end of period	$ 13,300

Note 6 - Debt and Other Finan_2

Note 6 - Debt and Other Financing Arrangements (Details Textual) - Credit Agreement [Member] - USD ($) $ in Millions	Aug. 01, 2018	Sep. 30, 2019
Long-term Debt, Total		$ 486.4
Term Loan [Member]
Debt Instrument, Face Amount	$ 250
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600
Line of Credit Facility, Additional Borrowing Capacity	$ 200
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.20%

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Variable Lease, Cost	$ 1
Fixed Lease, Cost	$ 3.2
Operating Lease, Expense		$ 12.9	$ 10.8	$ 9.8
Maximum [Member]
Lessee, Operating Lease, Renewal Term	5 years

Note 7 - Leases - Balance Sheet

Note 7 - Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019
Operating Lease, Right-of-Use Asset	$ 76,962	$ 0
Current operating lease liabilities	9,260	0
Noncurrent operating lease liabilities	72,870	$ 0
Total operating lease liabilities	$ 82,130
Weighted average remaining lease term (in years): (Year)	9 years 3 months 29 days
Weighted average discount rate:	4.40%

Note 7 - Leases - Cash Paid (De

Note 7 - Leases - Cash Paid (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2019USD ($)
Cash amounts paid on operating lease liabilities	$ 3,144
Right of use assets obtained in exchange for lease liabilities	$ 25

Note 7 - Leases - Fair Value of

Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) $ in Thousands	Sep. 30, 2019USD ($)
Remainder of 2020	$ 6,856
2021	9,017
2022	8,893
2023	8,616
2024	8,170
Thereafter	40,578
Total	$ 82,130

Note 7 - Leases - Aggregate Net

Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2020	$ 13,707
2021	13,469
2022	13,154
2023	12,716
2024	11,392
Thereafter	51,895
Total	$ 116,333

Note 8 - Supplemental Equity _3

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2019		Sep. 30, 2018	Sep. 30, 2020	Jun. 30, 2019	Jul. 01, 2018	Jun. 30, 2018
Common Stock, Dividends, Per Share, Declared	$ 0.32		$ 0.32
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0		$ 0
Stockholders' Equity Attributable to Parent, Ending Balance	1,174,224		1,109,469		$ 1,165,589		$ 1,079,061
Cumulative Effect of New Accounting Principle in Period of Adoption					(879)		594
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	(10,041)	[1]	0		(9,537)		0	[2]
AOCI Attributable to Parent [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	$ (91,627)		$ (70,632)		$ (83,521)		(44,814)
Cumulative Effect of New Accounting Principle in Period of Adoption							$ (24,682)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption						$ (24,682)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption						$ (24,682)
Forecast [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent				$ 3,907
[1]	The gain (loss) on the forward starting interest rate swap will be reclassified into earnings beginning October 31, 2019. Approximately ($3,907) of the ($10,041) will be reclassified into earnings in the 12 months subsequent to September 30, 2019.
[2]	As previously disclosed in our 10-K/A, unrealized gains of $24,682 on available-for-sale investments with readily determinable fair vales were included in the June 30, 2018 Consolidated Balance Sheet and were reclassified into retained earnings at the beginning of fiscal 2019 upon our adoption of ASU 2016-01 and ASU 2018-02. The amounts presented in accumulated other comprehensive income as of June 30, 2018 exclude these unrealized gains subsequently reclassified into retained earnings.

Note 8 - Supplemental Equity _4

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details) - USD ($)	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Balance (in shares)	37,934,040
Balance	$ 1,165,589,000	$ 1,079,061,000
Cumulative effect adjustments due to adoption of new accounting standards and other	(879,000)	594,000
Net earnings	14,398,000	17,403,000
Other comprehensive income (loss)	$ (8,106,000)	$ (1,136,000)
Common stock issued for exercise of options (in shares)	93,596	166,577
Common stock issued for exercise of options	$ 7,855,000	$ 15,611,000
Common stock issued for restricted stock awards	(1,926,000)	(2,405,000)
Cash dividends	(12,169,000)	(12,066,000)
Stock-based compensation expense	8,267,000	11,327,000
Common stock issued to employee stock purchase plan	1,096,000	842,000
Employee stock purchase plan expense	$ 99,000	238,000
Balance (in shares)	38,084,292
Balance	$ 1,174,224,000	$ 1,109,469,000
Common Stock [Member]
Balance (in shares)	37,934,000	37,608,000
Balance	$ 379,000	$ 376,000
Common stock issued for exercise of options (in shares)	94,000	166,000
Common stock issued for exercise of options	$ 1,000	$ 2,000
Common stock issued for restricted stock awards (in shares)	50,000	24,000
Common stock issued for restricted stock awards	$ 0	$ 0
Common stock issued to employee stock purchase plan (in shares)	6,000	5,000
Common stock issued to employee stock purchase plan	$ 0	$ 0
Balance (in shares)	38,084,000	37,803,000
Balance	$ 381,000	$ 378,000
Additional Paid-in Capital [Member]
Balance	316,797,000	246,568,000
Common stock issued for exercise of options	7,854,000	15,609,000
Common stock issued for restricted stock awards	0
Stock-based compensation expense	8,267,000	11,327,000
Common stock issued to employee stock purchase plan	1,096,000	842,000
Employee stock purchase plan expense	99,000	238,000
Balance	334,112,000	274,584,000
Retained Earnings [Member]
Balance	931,934,000	876,931,000
Cumulative effect adjustments due to adoption of new accounting standards and other	(879,000)	25,276,000
Net earnings	14,398,000	17,403,000
Common stock issued for restricted stock awards	(1,926,000)	(2,405,000)
Cash dividends	(12,169,000)	(12,066,000)
Balance	931,358,000	905,139,000
AOCI Attributable to Parent [Member]
Balance	(83,521,000)	(44,814,000)
Cumulative effect adjustments due to adoption of new accounting standards and other		(24,682,000)
Other comprehensive income (loss)	(8,106,000)	(1,136,000)
Balance	$ (91,627,000)	$ (70,632,000)

Note 8 - Supplemental Equity _5

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019		Sep. 30, 2018
Balance	$ 1,165,589		$ 1,079,061
Balance	1,174,224		1,109,469
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Balance	(9,537)		0	[1]
Other comprehensive income (loss), net of tax before reclassifications	(504)		0
Balance	(10,041)	[2]	0
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(73,983)		(69,496)	[1]
Other comprehensive income (loss), net of tax before reclassifications	(7,602)		(1,136)
Balance	(81,585)	[2]	(70,632)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Balance	(83,521)		(69,496)	[1]
Other comprehensive income (loss), net of tax before reclassifications	(8,106)		(1,136)
Balance	$ (91,627)	[2]	$ (70,632)
[1]	As previously disclosed in our 10-K/A, unrealized gains of $24,682 on available-for-sale investments with readily determinable fair vales were included in the June 30, 2018 Consolidated Balance Sheet and were reclassified into retained earnings at the beginning of fiscal 2019 upon our adoption of ASU 2016-01 and ASU 2018-02. The amounts presented in accumulated other comprehensive income as of June 30, 2018 exclude these unrealized gains subsequently reclassified into retained earnings.
[2]	The gain (loss) on the forward starting interest rate swap will be reclassified into earnings beginning October 31, 2019. Approximately ($3,907) of the ($10,041) will be reclassified into earnings in the 12 months subsequent to September 30, 2019.

Note 9 - Earnings Per Share (De

Note 9 - Earnings Per Share (Details Textual) - shares shares in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.2	1.3

Note 9 - Earnings Per Share - S

Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Net earnings	$ 14,398	$ 17,403
Income allocated to participating securities	(11)	(16)
Income available to common shareholders	$ 14,387	$ 17,387
Basic (in shares)	38,032	37,697
Basic (in dollars per share)	$ 0.38	$ 0.46
Net Income	$ 14,398	$ 17,403
Income available to common shareholders	$ 14,387	$ 17,387
Weighted average common shares outstanding-basic (in shares)	38,032	37,697
Dilutive effect of stock options and restricted stock units (in shares)	1,221	1,116
Diluted (in shares)	39,253	38,813
Diluted (in dollars per share)	$ 0.37	$ 0.45

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	700,000	900,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 190.39	$ 173.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 36.72	$ 34.30
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	93,596	166,577
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 11,600	$ 14,900
Share-based Payment Arrangement, Expense	8,800	11,565
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 45,700
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 1 month 6 days
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense	$ 8,400	$ 11,600
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	30,858	53,903
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 192.08	$ 170.74
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	11,438	11,279
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 190.65	$ 177.32

Note 11 - Other Income _ (Exp_3

Note 11 - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Interest expense	$ (5,222)	$ (5,239)
Interest income	111	102
Other non-operating income (expense), net	(10,410)	(3,040)
Total other income (expense)	$ (15,521)	$ (8,177)

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	19.10%	1.00%
Income Tax Expense (Benefit), Discrete Tax Items	$ (1.3)	$ 4.2
Excess Tax Benefit from Share-based Compensation, Operating Activities	3.2	3.4
Income Tax Expense (Benefit), Other Immaterial Discrete Tax Items, Net	$ 1.9	$ (0.8)

Note 13 - Segment Information -

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Revenues, net	$ 183,243	$ 162,970
Operating income	33,327	25,763
Costs recognized on sale of acquired inventory	0	(935)
Amortization of acquisition related intangible assets	(14,901)	(14,276)
Stock-based compensation, inclusive of employer taxes	(8,800)	(11,565)
Corporate general, selling, and administrative expenses	(69,010)	(67,051)
Operating Segments [Member]
Operating income	60,438	57,150
Operating Segments [Member] | Protein Sciences [Member]
Revenues, net	140,995	126,391
Operating income	59,538	54,614
Operating Segments [Member] | Diagnostics and Genomics [Member]
Revenues, net	42,552	36,747
Operating income	900	2,536
Intersegment Eliminations [Member]
Revenues, net	(304)	(168)
Segment Reconciling Items [Member]
Acquisition related expenses	(1,310)	(2,631)
Corporate, Non-Segment [Member]
Corporate general, selling, and administrative expenses	$ (2,100)	$ (1,980)